RonnyAllan.NET – Summary of November 2022

In the news – new Neuroendocrine Tumour PET Fluorine-18 based ‘tracer’

Incurable isn’t terminal

The Inspirational Wilko Johnson: 12 July 1947 – 21 November 2022

Neuroendocrine Neoplasms (NEN) – genetic related syndromes

Neuroendocrine Cancer: Those who know, know!

Ask More, Assume Less

Piss off Cancer, it’s been 12 years since my “big surgery”

Neuroendocrine Cancer: 10 questions your dietitian will ask

Neuroendocrine Cancer: Beware But Be Aware

Incidental Findings in Somatostatin Receptor PET (SSTR PET) scans (e.g. Ga68/Cu64)

RonnyAllan.NET – Summary of October 2022

Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ in Adult Subjects With SSTR positive NET

How are you, Doctor?

Benign liver lesions and cysts – something or nothing?

Understanding your Somatostatin Receptor (SSTR) PET Results

Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome

The Hidden Pheochromocytoma

New test of pancreatic cysts to help with cancer detection

Evidence of disease but stable

Study of Lu-177-DOTATATE (Lutathera) in Combination With PARP Inhibitors in Inoperable/Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Neuroendocrine Cancer: Glossary of Terms

Opinion: On Rare Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?

Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy

Living with cancer: 5 tips for facing things you can’t control

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

Neuroendocrine Cancer: When you get years added to your life, it’s important to get life added to your years

Opinion: Neuroendocrine Cancer – remission, cancer-free, no evidence of disease

Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)

Lung nodules – something or nothing?

Awareness Post – Neuroendocrine Cancer in children and adolescents

Eat that doughnut!

Thyroid nodules – something or nothing?

Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial

Prospective phase II trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin for prognostication in patients with neuroendocrine neoplasms

Neuroendocrine Cancer: At least 50 shades of grey

Curtis Crump: “If I’m going down, it won’t be without a fight.”

The trouble with the NET is that it can spread ……. false hope

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study

12 years – I’m still here!

Neuroendocrine Cancer: turn surveillance into a positive

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial

Neuroendocrine Cancer: diagnostic dilemmas in July 2010

CT scan findings in the COVID era: Ground Glass Opacities (GGO)

Me and the other big C – June/July 2022

New PET findings after COVID-19 vaccination: Keep Calm and Carry On?

Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors

CAPTEM for Neuroendocrine Tumours

Living with Cancer: Don’t cross the bridge until you come to it

Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma

Low and High Residue Foods

On the Cancer Journey, don’t forget to live your life

Histotripsy: A new technique which destroys cancer using soundwaves (now in Clinical Trials)

We are still here!

My illness may be invisible, but I am not – Neuroendocrine Cancer

Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)

Clinical Trial: Mycapssa (octreotide capsules) for Neuroendocrine Tumours

Clinical Trial: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

A Spotlight on Lung Neuroendocrine Neoplasms

The trouble with the NET (Part 5) – Cancer Diet Myths

External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy

Clinical Trial: Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Blog review and top 10 for 2021: RonnyAllan.NET

Neuroendocrine Cancer Diarrhea- building the jigsaw: Bile Acid Malabsorption

177Lu-DOTA-LM3 – a novel radionuclide therapy proven safe and effective to treat neuroendocrine neoplasms (NEN)

Small Intestine Neuroendocrine Tumours: “No other cancer really looks like this”

20th November 2010 – feeling perkier

Do we need a new model for Carcinoid Crisis in NETs?

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

CAR-T clinical trials for Neuroendocrine Cancer

Opinion: On World Neuroendocrine Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?

In the land of small tumours, there is still a lot of work to do!

The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability

Q. The best diet for Neuroendocrine Cancer? A. The one that works for you.

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – (COMPOSE)

New Clinical Trial – Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

The GRAIL multi-cancer early detection test study

Neuroendocrine Tumors: Targeted Therapies – Update from NET Specialist Diane Reidy-Lagunes, MD, Memorial Sloan-Kettering Cancer Center – August 2021

UK Travel Insurance – please give cancer patients a break!

I thought I was going to die. I didn’t

Small Intestine Neuroendocrine Tumours (SI NETs): To cut or not to cut?

Cancer-related fatigue (CRF) – Neuroendocrine Cancer

Let’s Talk About NETs (#LetsTalkAboutNETs)

11 years – I’m still here!

Neuroendocrine Cancer: 48 hours before diagnosis

Every picture tells a story (point, click, read)

A person with Neuroendocrine Cancer fell into a hole and couldn’t get out……….

A painting from America

The 6 E’s

I have walked 500 miles and I will walk 500 more (….. sing along)

Clinical Trial: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Neuroendocrine Tumour (VMT-𝛼-NET) programs

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumours

Generic Somatostatin Analogues for Neuroendocrine Cancer

A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours

A Neuroendocrine Cancer diagnosis: I didn’t even feel ill

Treatment for Neuroendocrine Cancer – a summary for patients

Ronny Allan Newsletter – 1st March 2021

Opinion: On Rare Disease Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?

My treatment is a pain in the butt!

Ronny Allan – Top 10 for 2020 – Neuroendocrine Cancer

Neuroendocrine Cancer: Follow up tests and checks

Neuroendocrine Cancer – I didn’t hear it coming

Opinion: On World Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?

Ronny Allan Newsletter – 1st February 2021

Lanreotide and Keytruda – the PLANET study (NCT03043664)

Currently trending on RonnyAllan.NET

The Invisibility of Appendiceal and Colorectal NETs – do the math

Ronny Allan Newsletter – 1st January 2021

A 2020 blog review (RonnyAllan.NET)

Genome methylation accurately predicts neuroendocrine tumor origin – finding Neuroendocrine Neoplasms of unknown primary

Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus

The other Big C can be dangerous too

Neuroendocrine Tumours – now you see them, now you don’t!

Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future

Lanreotide: Eleven more years please!

2 Million!

Ronny Allan Newsletter 1st December 2020

If it’s not raining, it’s not training! (part 2)

Ronny Allan Newsletter 1st November 2020

Piss off cancer – I’m 67

Early diagnosis of late stage cancer!

Serotonin – it’s a no-brainer!

Paul Hunter Tribute – Snooker champion and Neuroendocrine Cancer patient

Ronny Allan Newsletter 1st October 2020

Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency

I don’t look sick enough, sorry not sorry

Clinical Trial of Tidutamab in Neuroendocrine Cancer (DUET-1)

“I’m vertical” – Steve Jobs announces to Apple staff after a liver transplant

Flower power and the happy hormones

1.4 million thanks!

RonnyAllan.NET – Newsletter 1st September 2020

Small intestine, large surgery

RonnyAllan.NET – Newsletter 1st August 2020

Paraneoplastic endocrine syndromes – the NET effect

10 years, I’m still here

Don’t be cavalier with a cancer diagnosis

Neuroendocrine Cancer – no sweat!

After lockdown – the new normal is not normal

Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 12) – a story of surviving, cycling, Scottish holiday memories including the ‘Fairy Pools’

The NETest® – a Chromogranin A replacement and more?

RonnyAllan.NET – Newsletter 1st July 2020

SSTR PET – Ga68-DOTA-JR11 vs Ga68-DOTATATE

Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 11) – a story of Walking the Wall, coping strategies and the London Ga68 PET

Targeted Therapy for Neuroendocrine Cancer – Sunitinib (Sutent)

Targeted Therapy for Neuroendocrine Cancer – Everolimus (Afinitor)

Ronny Allan: Living with Neuroendocrine Cancer during lockdown (Episode 10) – A story of the Wall, Swans, Dundee and New Forest History

My interview with ITM – I’m still here!

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 9) – a story of cream teas, peaks and blue sky

RonnyAllan.NET – Newsletter 1st June 2020

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 8) – a story of nurses, trees and Canada

Ronny Allan: Living with Neuroendocrine Cancer during lockdown restrictions (Episode 7) – A story of swans, cycling, VE Day and my 124th monthly cancer treatment

Ronny Allan: Living with Neuroendocrine Cancer during lockdown restrictions (Episode 6) – A story of footpath etiquette, sheep, donkeys and dopamine

Ronny Allan: Living with Neuroendocrine Cancer during lockdown (Episode 5) – A story of greenery, sun, adventure and Irrfan

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 4) – A story of bikes, ponies, wisteria and Vitamin D 

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 3) – An injection, hair cut and a broken tooth

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 2) – the bench walk

Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 1) – out of isolation

Neuroendocrine Cancer Surgery 3: my distant lymph nodes

We Remember – A message of hope in the time of the Coronavirus!

My Self Isolation Diary – COVID-19

COVID-19 and Cancer Treatment and Surveillance

Why Coronavirus Anxiety is Hard to Control – a Neuroendocrine Cancer patient perspective

Coronavirus 19 (COVID-19): risks for cancer patients

Neuroendocrine Cancer Nutrition Series Part 6 – featuring the 2020 video series by Tara Whyand RD

Clinical Trial: Lu-177 DOTATOC (PRRT) in adult subjects with Somatostatin receptor (SSTR) positive Pulmonary, Pheochromocytoma, Paraganglioma,  Unknown primary, and Thymic Neuroendocrine Tumors

Oral Octreotide using RaniPill™

Neuroendocrine Cancer: The Perfect Storm

Neuroendocrine Cancer – Liver directed therapy

Featuring Kirsty Dalglish – Pheochromocytoma and Pregnancy

Ronny Allan – Top 10 for 2019 – Neuroendocrine Cancer

NETDetect: Earlier diagnosis of Neuroendocrine Cancer gets a boost

Prognostics and Crystal Balls

Olivia Williams – Neuroendocrine Cancer (VIPoma)

“Please find something wrong with me”

Neuroendocrine Cancer: Double, Double Toil and Trouble

The Flu shot – it’s not just about you

Clinical Trials – PEN-221 for Neuroendocrine Cancer

Clinical Trials – ONC201 for Neuroendocrine Cancer (including Pheo/Para)

The Other 5 E’s

The Case of Justice Ruth Bader Ginsburg vs Cancer

Surufatinib for Neuroendocrine Cancer

The trouble with the NET (Part 4) – Cancer can kill but so can fake cures

Pancreatic Neuroendocrine Tumours – to cut or not to cut

Clinical Trials of PV-10 (Rose Bengal) for the treatment of Neuroendocrine Tumours (NET)

New Radiotracer Can Identify Nearly 30 Types of Cancer – SNMMI – 68Ga-FAPI PET/CT

LUTATHERA (PRRT) – NETTER 2 Clinical Trial for Grade 2/Grade 3 Patients Advanced GEP-NET (NETTER-2)

Clinical Trial of Paltusotine for the Treatment of Neuroendocrine Tumours

The Heterogeneity of Grade 3 (High grade) Neuroendocrine Neoplasms

Clinical Trial: Treatment of IBS with diarrhoea – titrated ondansetron (TRITON)

I’m not sick, I just have cancer

Rosacea – the NET Effect

Neuroendocrine Cancer: No one gets it until they get it!

From dying to living, to hell and back

“I Knew There Was Something Wrong, But I Didn’t Know What” — A Nurse Shares Her Cancer Story

Letter from America

Proton Pump Inhibitors (…..and H2 Blockers) the NET Effect

Clinical Trial: Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (TALENT)

Clinical Trial: Intra-arterial Lu177 (PRRT) for Neuroendocrine Cancer liver metastases (LUTIA)

Clinical Trial SPARTALIZUMAB – Immunotherapy for Neuroendocrine Neoplasms (PDR001)

Breath test with the goal of detecting multiple cancers – ready to start trials

Q-Sphera™ – Next Generation Somatostatin Analogue delivery system?

Neuroendocrine Cancer: a needle in a haystack?

Neuroendocrine Cancer Clinical Trial – Lutetium-177 OPS-201 (Satoreotide)

RonnyAllan.NET – Community Newsletter Covering November 2018

Neuroendocrine Cancer – is normally slow growing BUT …..

Pancreatic Cancer vs Neuroendocrine Cancer of Pancreatic Origin

RonnyAllan.NET – Community Newsletter Covering October 2018

Neuroendocrine Cancer Hormonal Syndromes – Clinical Esoterica

How to Talk to a Cancer Patient Without Being a Complete Twit

Living with Cancer – Worrier or Warrior?

Neuroendocrine Cancer – Short Update from NANETS 2018

Neuroendocrine Cancer – on your bike!

RonnyAllan.NET – Community Newsletter Covering September 2018

Don’t worry, it’s benign!

Diabetes – The NET Effect

Neuroendocrine Cancer: Diagnosing the Undiagnosed

Neuroendocrine Cancer is not a ‘type’ of another Cancer ….. PERIOD!

RonnyAllan.NET – Community Newsletter Covering August 2018

Detectnet™ (64Cu-DOTATATE) – an expansion of the Somatostatin Receptor PET Imaging for Neuroendocrine Cancer

Aretha Franklin 1942-2018: Neuroendocrine Cancer

I wish I had another cancer

RonnyAllan.NET – Community Newsletter JULY 2018

Neuroendocrine Cancer: Ga68 PET Scan – a game changer?

Neuroendocrine Cancer: Fibrosis – an unsolved mystery?

“What are you doing this afternoon”

177Lu-DOTA-EB-TATE – Long-lasting radionuclide therapy for advanced neuroendocrine tumors proves effective

RonnyAllan.NET – Community Newsletter JUNE 2018

RonnyAllan.NET – Community Newsletter May 2018

All you need to know about Somatostatin Receptor PET/CT Scans for Neuroendocrine Tumours

RonnyAllan.NET – Community Newsletter April 2018

Sapanisertib – a drug on trial for Neuroendocrine Tumors (NET) with a pancreatic primary

RonnyAllan.NET – Community Newsletter March 2018

Irrfan Khan

RonnyAllan.NET – Community Newsletter February 2018

Update – Oncolytic Virus Trials for Neuroendocrine Cancer

Things to do today

Don’t be underactive with your Thyroid surveillance

Neuroendocrine Cancer Clinical Trial: Advanced Oncology Formula enterade®

RonnyAllan.NET – Community Newsletter January 2018

I now take food with my medicine!

BREAKING NEWS – US FDA Approves Lutetium Lu 177 dotatate (Lutathera®) – PRRT?

Shame on you!

Neuroendocrine Cancer and Pancreatic Enzyme Replacement Therapy (PERT) – the Digested Version (Nutrition Series Article 5)

Targeted Alpha-emitter Therapy (TAT) – the wave of the future in nuclear oncology/PRRT?

NETwork with Ronny © – Community Newsletter DECEMBER 2017

Ronny Allan – Top 6 posts of 2017

Neuroendocrine Cancer – surveillance and follow up

Update: Management of Neuroendocrine Tumors

Phase 3 Clinical Trial of 177Lu-Edotreotide (Solucin®) – COMPETE for GEPNETs

NETwork with Ronny © – Community Newsletter NOVEMBER 2017

Living with Neuroendocrine Cancer – the 7 Year Itch

NETwork with Ronny © – Community Newsletter OCTOBER 2017

Neuroendocrine Cancer – normally slow but always sneaky

Round up of NANETS 2017 – Let’s talk about NETs #NANETS2017

Opinion: Neuroendocrine Cancer – Can it be cured?

Weight – the NET Effect

The shock effect never wears off

Genetics and Neuroendocrine Tumors

Cancer Isn’t All About Me

NETwork with Ronny © – Community Newsletter SEPTEMBER 2017

Ever wonder what caused your Neuroendocrine Cancer?

Categories, tissues and primary sites – the lost awareness of Neuroendocrine Cancer

NETwork with Ronny © – Community Newsletter AUGUST 2017

The Invisible NET Patient Population 

Lanreotide for Lung NETs – SPINET Clinical Trial

NETwork with Ronny © – Community Newsletter JULY 2017

At home with Lanreotide (….and Octreotide)

NETwork with Ronny © – Community Newsletter JUNE 2017

Immunotherapy: Studies with Neuroendocrine Neoplasms

Ronny Allan’s ‘PoNETry’ © – An Ode to Invisible Illness

Ronny Allan’s ‘PoNETry’ © – An Ode to Lanreotide

8 tips for conquering fear – Living with Neuroendocrine Cancer

NETwork with Ronny © – Community Newsletter MAY 2017

ASCO 2017 – Let’s talk about NETs #ASCO17

All you need to know about Peptide Receptor Radionuclide Therapy (PRRT)

NETwork with Ronny © – Newsletter April 2017

The trouble with the NET (Part 3) – Miracle Cures

Diagnosed with Neuroendocrine Cancer? – 10 questions to ask your doctor (and where to find a NET Specialist Worldwide)

Don’t believe the hype – Neuroendocrine Cancer Myths debunked

There’s no such thing as a ‘tickbox’ Neuroendocrine Cancer patient

NETwork with Ronny © – Newsletter March 2017

In the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life

Poker Face or Cancer Card?

NETwork with Ronny © – Newsletter February 2017

It’s been 10 years since I saw a scalpel (….but my surgeon is still on speed dial)

Recent Progress in NET Management – Positive presentation from Jonathan R Strosberg MD

25 Life Lessons From a Two-Time Cancer Survivor

Things not to say to someone with cancer

NETwork with Ronny © – Newsletter January 2017

Endoscopy for NETs – taking the camera to the tumour

Road ahead closed – Bowel Obstructions

Clinical Trial – Cabozantinib for Neuroendocrine Neoplasms

Theranostics for Neuroendocrine Cancer – A Find and Destroy Mission

Neuroendocrine Cancer: Nodes, Nodules, Lesions (and false alarms!)

Surgery for Neuroendocrine Neoplasms – to cut or not to cut?

Does your body now have an extra organ? The MESENTERY

NETwork with Ronny © – Newsletter December 2016

Somatostatin Analogues for Neuroendocrine Cancer: Lanreotide and Octreotide

Keep your lights burning